153 related articles for article (PubMed ID: 23110309)
41.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
42. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
Rudenko HC; Else M; Dearden C; Brito-Babapulle V; Jones C; Dexter T; Fenwick K; Mackay A; Ashworth A; Matutes E; Gonzalez D; Catovsky D; Morgan GJ
Leuk Lymphoma; 2008 Oct; 49(10):1879-86. PubMed ID: 18949611
[TBL] [Abstract][Full Text] [Related]
43. TP53 dysfunction in CLL: Implications for prognosis and treatment.
Te Raa GD; Kater AP
Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075
[TBL] [Abstract][Full Text] [Related]
44. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
Fink SR; Smoley SA; Stockero KJ; Paternoster SF; Thorland EC; Van Dyke DL; Shanafelt TD; Zent CS; Call TG; Kay NE; Dewald GW
Cancer Genet Cytogenet; 2006 Jun; 167(2):177-81. PubMed ID: 16737921
[TBL] [Abstract][Full Text] [Related]
45. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
Messmer BT; Nour-Omid TS; Ghia E; Sanchez AB; Kipps TJ
Leuk Res; 2011 Jul; 35(7):965-7. PubMed ID: 21570119
[TBL] [Abstract][Full Text] [Related]
46. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
47. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
48. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Chapiro E; Lesty C; Gabillaud C; Durot E; Bouzy S; Armand M; Le Garff-Tavernier M; Bougacha N; Struski S; Bidet A; Laharanne E; Barin C; Veronese L; Prié N; Eclache V; Gaillard B; Michaux L; Lefebvre C; Gaillard JB; Terré C; Penther D; Bastard C; Nadal N; Fert-Ferrer S; Auger N; Godon C; Sutton L; Tournilhac O; Susin SA; Nguyen-Khac F;
Am J Hematol; 2018 Mar; 93(3):375-382. PubMed ID: 29194741
[TBL] [Abstract][Full Text] [Related]
49. Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation.
Diamantopoulos PT; Samara S; Kollia P; Giannakopoulou N; Sofotasiou M; Kalala F; Kodandreopoulou E; Zervakis P; Vassilakopoulos T; Siakantaris M; Mantzourani M; Angelopoulou M; Kyrtshonis MC; Korkolopoulou P; Patsouris E; Viniou NA
Anticancer Res; 2017 May; 37(5):2387-2391. PubMed ID: 28476805
[TBL] [Abstract][Full Text] [Related]
50. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
[TBL] [Abstract][Full Text] [Related]
51. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G; Tausch E; Eclache V; Sebaa A; Bianchi V; Letestu R; Collon JF; Lefebvre V; Gardano L; Varin-Blank N; Soussi T; Stilgenbauer S; Cymbalista F; Baran-Marszak F
Int J Cancer; 2016 Oct; 139(8):1759-63. PubMed ID: 27270786
[TBL] [Abstract][Full Text] [Related]
52. [TP53 mutation analysis in chronic lymphocytic leukaemia].
Fésüs V; Marosvári D; Kajtár B; Király PA; Demeter J; Gurbity Pálfi T; Egyed M; Plander M; Farkas P; Mátrai Z; Matolcsy A; Bödör C
Orv Hetil; 2017 Feb; 158(6):220-228. PubMed ID: 28166664
[TBL] [Abstract][Full Text] [Related]
53. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.
Forconi F; Rinaldi A; Kwee I; Sozzi E; Raspadori D; Rancoita PM; Scandurra M; Rossi D; Deambrogi C; Capello D; Zucca E; Marconi D; Bomben R; Gattei V; Lauria F; Gaidano G; Bertoni F
Br J Haematol; 2008 Nov; 143(4):532-6. PubMed ID: 18752589
[TBL] [Abstract][Full Text] [Related]
54. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
55. TP53 aberrations in chronic lymphocytic leukemia.
Trbusek M; Malcikova J
Adv Exp Med Biol; 2013; 792():109-31. PubMed ID: 24014294
[TBL] [Abstract][Full Text] [Related]
56. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome.
Callet-Bauchu E; Salles G; Gazzo S; Poncet C; Morel D; Pagès J; Coiffier B; Coeur P; Felman P
Leukemia; 1999 Mar; 13(3):460-8. PubMed ID: 10086737
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
58. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
59. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
[TBL] [Abstract][Full Text] [Related]
60. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Zenz T; Vollmer D; Trbusek M; Smardova J; Benner A; Soussi T; Helfrich H; Heuberger M; Hoth P; Fuge M; Denzel T; Häbe S; Malcikova J; Kuglik P; Truong S; Patten N; Wu L; Oscier D; Ibbotson R; Gardiner A; Tracy I; Lin K; Pettitt A; Pospisilova S; Mayer J; Hallek M; Döhner H; Stilgenbauer S;
Leukemia; 2010 Dec; 24(12):2072-9. PubMed ID: 20861914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
